Immutep (STU:YP1A) FFO


STU:YP1A Immutep Ltd STU:YP1A
23 GF Score
Price €0.37
! 1 Warning Sign
View Full Analysis

What is Immutep FFO?

FFO (Funds from operations) only applies to REITs.

STU:YP1A
23GF Score
Immutep Ltd STU:YP1A
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immutep Business Description

Address 264 George Street, Level 32, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
23GF Score

Get the complete analysis for STU:YP1A

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.37
Price